靶向JAK/STAT通路治疗大动脉炎
该研究分析了大动脉炎(TAK)患者CD4+和CD8+ T细胞的转录组和干扰素基因特征,发现JAK/STAT通路及I/II型干扰素信号显著富集。体外和体内实验显示JAK抑制剂可降低CD25表达、减少Th1和Th17细胞、增加Treg细胞,并降低C反应蛋白、NIH评分和糖皮质激素剂量,提示JAKinibs可能是有前景的疗法。
要点
- TAK患者CD4+和CD8+ T细胞中I/II型干扰素及JAK/STAT通路基因显著富集。
- JAK抑制剂体外和体内均降低CD25表达、减少Th1/Th17并增加Treg。
- JAK抑制剂降低TAK患者CRP、NIH评分和糖皮质激素剂量。
核心结论
- JAK/STAT信号通路在TAK发病机制中起关键作用,JAK抑制剂可能是TAK有前景的治疗选择。
研究设计与样本
- 研究纳入25例TAK患者(中位年龄37.6岁,其中21例为NIH评分>1的活动性TAK)和健康供者,对分选CD4+和CD8+ T细胞进行转录组和干扰素基因特征分析,并在体外和体内测试JAK抑制剂的效果。
主要发现
- 转录组分析显示健康供者与TAK之间CD4+样本有248个、CD8+样本有432个显著失调基因。
- 失调基因中I型和II型干扰素、JAK/STAT及细胞因子/趋化因子相关信号通路显著富集。
- RT-qPCR证实TAK中I型干扰素基因特征较健康供者上调。
- JAK抑制剂体外和体内均显著降低CD4+和CD8+ T细胞的CD25表达,显著减少Th1和Th17细胞并增加Treg细胞。
- JAK抑制剂降低TAK患者的C反应蛋白水平、NIH评分和糖皮质激素剂量。
关键数值与推荐
- TAK患者中位年龄37.6岁,25例中21例为活动性TAK(NIH评分>1)。
- CD4+和CD8+ T细胞分别有248和432个显著失调基因。
临床怎么用
- JAK抑制剂可能用于降低TAK患者炎症指标、疾病活动度和糖皮质激素用量,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Takayasu's arteritis (TAK) is a large vessel vasculitis with important infiltration of proinflammatory T cells in the aorta and its main branches, but its aetiology is still unknown. Our work aims to explore the involvement of Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signalling pathway in proinflammatory T cells differentiation and disease activity of TAK. METHODS: We analysed transcriptome and interferons gene signatures of fluorescence-activated cell sorting (FACS-sorted) CD4+ and CD8+ T cells from healthy donors (HD) and in 25 TAK (median age of 37.6 years including 21 active TAK with National Institutes of Health (NIH) score >1). Then we tested, in vitro and in vivo, the effects of JAK inhibitors (JAKinibs) in TAK. RESULTS: Transcriptome analysis showed 248 and 432 significantly dysregulated genes for CD4+ and CD8+ samples between HD and TAK, respectively. Among dysregulated genes, we highlighted a great enrichment for pathways linked to type I and type II interferons, JAK/STAT and cytokines/chemokines-related signalling in TAK. We confirmed by Real Time Reverse Transcription Polymerase Chain Reaction (RT-qPCR) the upregulation of type I interferons gene signature in TAK as compared with HD. JAKinibs induced both in vitro and in vivo a significant reduction of CD25 expression by CD4+ and CD8+ T cells, a significant decrease of type 1 helper T cells (Th1) and Th17 cells and an increase of Tregs cells in TAK. JAKinibs also decreased C reactive protein level, NIH score and corticosteroid dose in TAK patients. CONCLUSIONS: JAK/STAT signalling pathway is critical in the pathogenesis of TAK and JAKinibs may be a promising therapy.
引用
- Régnier P, Le Joncour A, Maciejewski-Duval A, et al. Targeting JAK/STAT pathway in Takayasu's arteritis. Ann Rheum Dis. 2020. PMID: 32213496. doi:10.1136/annrheumdis-2019-216900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。